Multiple studies provide convincing evidence that antigen-dependent co-stimulation through CD28-targeting bispecific T-cell engager antibodies is an effective strategy to specifically increase T-cell activation in vitro (19, 48) and enhance anti-tumor activity in vivo (46, 49). This evidence concerns the gene CD28 and neoplasm.